Display options
Cite
Williams CB, McMahon C, Ali SM, et al. A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. Onco Targets Ther. 2015;8:3561-4doi: 10.2147/OTT.S90766.
Williams, C. B., McMahon, C., Ali, S. M., Abramovitz, M., Williams, K. A., Klein, J., McKean, H., Yelensky, R., George, T. J., Elvin, J. A., Soman, S., Lipson, D., Chmielecki, J., Morosini, D., Miller, V. A., Stephens, P. J., Ross, J. S., & Leyland-Jones, B. (2015). A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. OncoTargets and therapy, 83561-4. https://doi.org/10.2147/OTT.S90766
Williams, Casey B, et al. "A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy." OncoTargets and therapy vol. 8 (2015): 3561-4. doi: https://doi.org/10.2147/OTT.S90766
Williams CB, McMahon C, Ali SM, Abramovitz M, Williams KA, Klein J, McKean H, Yelensky R, George TJ, Elvin JA, Soman S, Lipson D, Chmielecki J, Morosini D, Miller VA, Stephens PJ, Ross JS, Leyland-Jones B. A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. Onco Targets Ther. 2015 Dec 01;8:3561-4. doi: 10.2147/OTT.S90766. eCollection 2015. PMID: 26664139; PMCID: PMC4671814.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2015 Dec 01;8:3561-4. doi: 10.2147/OTT.S90766. eCollection 2015.

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.

OncoTargets and therapy

Casey B Williams, Caitlin McMahon, Siraj M Ali, Mark Abramovitz, Kirstin A Williams, Jessica Klein, Heidi McKean, Roman Yelensky, Thomas J George, Julia A Elvin, Salil Soman, Doron Lipson, Juliann Chmielecki, Deborah Morosini, Vincent A Miller, Philip J Stephens, Jeffrey S Ross, Brian Leyland-Jones

Affiliations

  1. Avera Cancer Institute, Sioux Falls, SD, USA.
  2. Foundation Medicine, Inc., Cambridge, MA, USA.
  3. University of Florida College of Medicine, Gainesville, FL, USA.
  4. Beth Israel Deaconess Medical Center, Boston, MA, USA.
  5. Foundation Medicine, Inc., Cambridge, MA, USA ; Albany Medical College, Albany, NY, USA.

PMID: 26664139 PMCID: PMC4671814 DOI: 10.2147/OTT.S90766

Abstract

The subset of metastatic colorectal adenocarcinomas that harbor BRAF V600E mutations are aggressive tumors with significantly shortened survival and limited treatment options. Here we present a colorectal cancer patient whose disease progressed through standard chemotherapy and who developed liver metastasis. Comprehensive genomic profiling (FoundationOne(®)) identified a BRAF V600E mutation in the liver lesion, as well as other genomic alterations consistent with colorectal cancers. Combination therapy of dabrafenib and trametinib with standard cytotoxic chemotherapy resulted in a durable major ongoing response for the patient. This report illustrates the utility of comprehensive genomic profiling with personalized targeted therapy for aggressive metastatic colorectal adenocarcinomas.

Keywords: BRAF mutations; colorectal adenocarcinoma; combination targeted therapy; oxaliplatin

References

  1. Cancer Discov. 2012 Mar;2(3):227-35 - PubMed
  2. Cancer. 2013 Dec 1;119(23 ):4137-44 - PubMed
  3. Nature. 2002 Jun 27;417(6892):949-54 - PubMed
  4. J Surg Oncol. 2012 Aug 1;106(2):123-9 - PubMed
  5. Nature. 2012 Jul 18;487(7407):330-7 - PubMed
  6. Nature. 2012 Jul 26;487(7408):500-4 - PubMed
  7. Curr Oncol. 2014 Feb;21(1):e151-4 - PubMed
  8. Nat Biotechnol. 2013 Nov;31(11):1023-31 - PubMed
  9. J Clin Oncol. 2015 Dec 1;33(34):4023-31 - PubMed
  10. Clin Cancer Res. 2015 Mar 15;21(6):1313-20 - PubMed
  11. Cancer Discov. 2015 Apr;5(4):358-67 - PubMed
  12. J Natl Cancer Inst. 2014 Jun 12;106(7):null - PubMed
  13. Br J Cancer. 2009 Aug 4;101(3):465-72 - PubMed
  14. J Clin Oncol. 2013 Jun 1;31(16):1913-6 - PubMed

Publication Types